Breast Cancer Resistance Protein (BCRP/ABCG2) Induces Cellular Resistance to HIV-1 Nucleoside Reverse Transcriptase Inhibitors
- 1 January 2003
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Molecular Pharmacology
- Vol. 63 (1), 65-72
- https://doi.org/10.1124/mol.63.1.65
Abstract
Breast cancer resistance protein (BCRP/ABCG2) is a novel member of ATP- binding cassette transporters, which induce multidrug resistance in cancer cells. We found that a high level of BCRP expression in CD4+ T cells conferred cellular resistance to human immunodeficiency virus type-1 (HIV-1) nucleoside reverse transcriptase inhibitors. The cell line MT-4/DOX500 was established through the long-term culture of MT-4 cells in the presence of doxorubicin (DOX) and had reduced sensitivity to not only DOX but also zidovudine (AZT). MT-4/DOX500 cells showed reduced intracellular accumulation and retention of DOX and increased ATP-dependent rhodamine 123 efflux. The cells were also resistant to several anticancer agents such as mitoxantrone, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, and 7-ethyl-10-hydroxycamptothecin. AZT was 7.5-fold less inhibitory to HIV-1 replication in MT-4/DOX500 cells than in MT-4 cells. Furthermore, the anti–HIV-1 activity of lamivudine was severely impaired in MT-4/DOX500 cells. In contrast, the antiviral activity of non-nucleoside reverse transcriptase inhibitors and protease inhibitors was not affected in the cells. MT-4/DOX500 cells expressed glycosylated BCRP but not P-glycoprotein (ABCB1), multidrug resistance protein 1, 2, or 4 (ABCC1, -2, or -4), or lung resistance-related protein. In addition, the BCRP-specific inhibitor fumitremorgin C completely abolished the resistance of MT-4/DOX500 cells to AZT as well as to DOX. An analysis for intracellular metabolism of AZT suggests that the resistance is attributed to the increase of ATP-dependent efflux of its metabolites, presumably AZT 5′-monophosphate, in MT-4/DOX500 cells.Keywords
This publication has 29 references indexed in Scilit:
- Effect of Multidrug Resistance-Reversing Agents on Transporting Activity of Human Canalicular Multispecific Organic Anion TransporterMolecular Pharmacology, 1999
- A multidrug resistance transporter from human MCF-7 breast cancer cellsProceedings of the National Academy of Sciences, 1998
- Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAARTProceedings of the National Academy of Sciences of the United States of America, 1998
- Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV diseaseAIDS, 1997
- The neuropathogenesis of HIV-1 infectionJournal of Leukocyte Biology, 1994
- Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitroAntimicrobial Agents and Chemotherapy, 1994
- Resistance of HIV-1 to AZT Might Also Involve the Cellular Expression of Multidrug Resistance P-GlycoproteinAIDS Research and Human Retroviruses, 1992
- Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.Proceedings of the National Academy of Sciences of the United States of America, 1991
- Isolation and genetic characterization of human KB cell lines resistant to multiple drugsSomatic Cell and Molecular Genetics, 1985
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976